Abstract
Risk-reducing salpingo-oophorectomy is currently advocated for the reduction of both breast and ovarian cancer risk in BRCA1/2 carriers, but residual risk of peritoneal primary cancer remains a concern. A sequential series of women attending a single institution for ovarian risk management underwent either risk-reducing surgery or screening. A person-years at risk analysis was used to compare observed versus expected cancers. In total, 300 women underwent risk-reducing salpingo-oophorectomy, including 160 BRCA1/2 mutation carriers. Three occult ovarian cancers were detected at surgery. There have been 2400.4 years of follow-up and 15.79 expected cancers. No peritoneal cancers have occurred. Amongst 503 women controls with 3444.3 years of follow-up, 15.93 ovarian cancers were expected and 17 were found. There were six ovarian cancer-related deaths in the control group compared with one in the surgery group. Risk-reducing salpingo-oophorectomy in a single institution has so far avoided peritoneal cancer incidence.
Similar content being viewed by others
Log in or create a free account to read this content
Gain free access to this article, as well as selected content from this journal and more on nature.com
or
References
Young RC, Walton LA, Ellenberg SS et al: Adjuvant therapy in stage I and stage II epithelial ovarian cancers. Results of two prospective randomised trials. N Engl J Med 1990; 322: 1021–1027.
Evans DGR : Risk estimation in ovarian cancer; in Lalloo F, Kerr B, Friedman J, Evans DGR (eds): Risk Assessment and Management in Cancer Genetics. Oxford University Press, Oxford, 2005, pp 73–82.
Chappius PO, Foulkes WD : Overview of the clinical genetics of ovarian cancer; in Morrison PJ, Hodgson SV, Haites NE (eds): Familial Breast and Ovarian Cancer: Genetics, Screening and Management. Cambridge University Press, Cambridge, 2002, pp 43–72.
Stratton JF, Pharoah P, Smith SK, Easton D, Ponder BA : A systematic review and meta-analysis of family history and risk associated with ovarian cancer. Br J Obstet Gynaecol 1998; 105: 493–499.
Risch HA, McLaughlin JR, Cole DE et al: Population BRCA1 and BRCA2 mutation frequencies and cancer penetrances: a kin-cohort study in Ontario, Canada. J Natl Cancer Inst 2006; 98: 1694–1706.
Thompson D, Easton DF : Cancer Incidence in BRCA1 mutation carriers. J Natl Cancer Inst 2002; 94: 1358–1365.
Moller P, Hagen AI, Apold J et al: Genetic epidemiology of BRCA mutation–family history identifies less than 50% of mutation carriers. Eur J Cancer 2007; 43: 1713–1717.
Ford D, Easton DF, Stratton M et al: Genetic heterogeneity and penetrance analysis of the BRCA1 and BRCA2 genes in breast cancer families. The Breast Cancer Linkage Consortium. Am J Hum Genet 1998; 62: 676–689.
Aarnio M, Sankila R, Pukkala E et al: Cancer risk in mutation carriers of DNA-mismatch-repair genes. Int J Cancer 1999; 81: 214–218.
Hogg R, Freidlander M : Biology of epithelial ovarian cancer: implications for screening women at high genetic risk. J Clin Oncol 2004; 22: 1315–1327.
Hermsen BB, Olivier RI, Verheijen RH et al: No efficacy of annual gynaecological screening in BRCA1/2 mutation carriers; an observational follow-up study. Br J Cancer 2007; 96: 1335–1342.
Gaarenstroom KN, van der Hiel B, Tollenaar RA et al: Efficacy of screening women at high risk of hereditary ovarian cancer: results of an 11-year cohort study. Int J Gynecol Cancer 2006; 16 (Suppl 1): 54–59.
Dorum A, Heimdal K, Lovslett K et al: Prospectively detected cancer in familial breast/ovarian cancer screening. Acta Obstet Gynecol Scand 1999; 78: 906–911.
Stirling D, Evans DG, Pichert G et al: Familial ovarian cancer screening: current protocols are ineffective in detecting early stage ovarian malignancy. J Clin Oncol 2005; 23: 5588–5596.
Munkarah A, Chatterjee M, Tainsky MA : Update on ovarian cancer screening. Curr Opin Obstet Gynecol 2007; 19: 22–26.
Rebbeck TR, Kauff ND, Domchek SM : Meta-analysis of risk reduction estimates associated with risk-reducing salpingo-oophorectomy in BRCA1 or BRCA2 mutation carriers. J Natl Cancer Inst 2009; 101: 80–87.
Rebbeck TR, Lynch HT, Neuhausen SL et al: Prevention and observation of surgical end points study group. Prophylactic oophorectomy in carriers of BRCA1 or BRCA2 mutations. N Engl J Med 2002; 346: 1616–1621.
Kauff ND, Domchek SM, Friebel TM et al: Risk-reducing salpingo-oophorectomy for the prevention of BRCA1- and BRCA2-associated breast and gynecologic cancer: a multicenter, prospective study. J Clin Oncol 2008; 26: 1331–1337.
Kauff ND, Satagopan JM, Robson ME et al: Risk-reducing salpingo-oophorectomy in women with a BRCA1 or BRCA2 mutation. N Engl J Med 2002; 346: 1609–1615.
Piver MS, Jishi MF, Tsukada Y, Nava G : Primary peritoneal carcinoma after prophylactic oophorectomy in women with a family history of ovarian cancer. A report of the Gilda Radner Family Ovarian Cancer Registry. Cancer 1993; 71: 2751–2755.
Evans DG, Gaarenstroom KN, Stirling D et al: Screening for familial ovarian cancer: poor survival of BRCA1/2 related cancers. J Med Genet 2008 [E-pub ahead of print].
Powell CB, Kenley E, Chen LM et al: Risk-reducing salpingo-oophorectomy in BRCA mutation carriers: role of serial sectioning in the detection of occult malignancy. J Clin Oncol 2005; 23: 127–132.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Evans, D., Clayton, R., Donnai, P. et al. Risk-reducing surgery for ovarian cancer: outcomes in 300 surgeries suggest a low peritoneal primary risk. Eur J Hum Genet 17, 1381–1385 (2009). https://doi.org/10.1038/ejhg.2009.60
Received:
Revised:
Accepted:
Published:
Issue date:
DOI: https://doi.org/10.1038/ejhg.2009.60
Keywords
This article is cited by
-
Prophylactic salpingo-oophorectomy in BRCA1 mutation carriers and postoperative incidence of peritoneal and breast cancers
Journal of Ovarian Research (2016)
-
Endometrium is not the primary site of origin of pelvic high-grade serous carcinoma in BRCA1 or BRCA2 mutation carriers
Modern Pathology (2013)
-
Risk-reducing surgery increases survival in BRCA1/2 mutation carriers unaffected at time of family referral
Breast Cancer Research and Treatment (2013)
-
Catalysts to withdrawal from familial ovarian cancer screening for surgery and reactions to discontinued screening: a qualitative study
Familial Cancer (2013)
-
Uptake of risk-reducing salpingo-oophorectomy in women carrying a BRCA1 or BRCA2 mutation: evidence for lower uptake in women affected by breast cancer and older women
British Journal of Cancer (2012)
